OMISIRGE® (omidubicel)
Hematologic malignancies (post-myeloablative conditioning)
ApprovedCommercial
Key Facts
Indication
Hematologic malignancies (post-myeloablative conditioning)
Phase
Approved
Status
Commercial
Company
About Gamida Cell
Gamida Cell pioneers nicotinamide-enhanced allogeneic cell therapies for hematologic conditions, with two FDA-approved products for transplantation and stem cell mobilization.
View full company profileAbout Gamida Cell
Gamida Cell pioneers nicotinamide-enhanced allogeneic cell therapies for hematologic conditions, with two FDA-approved products for transplantation and stem cell mobilization.
View full company profile